GC Cell, a contract development and manufacturing organization (CDMO) for cell and gene therapies, said Thursday that it has ushered in Kang Jin-hee, a clinical development and global regulatory expert, as its chief development officer to strengthen its R&D capabilities.

According to GC Cell, the new CDO Kang brings extensive experience and expertise in the global biopharmaceutical market, including business planning and management.

Kang has been head of global strategy and chief regulatory officer at NeoImmuneTech. The company added that she contributed to developing a new T-cell-based immuno-oncology and infectious disease therapeutics pipeline and established U.S. and European approval strategies.

Kang also served as head of global product development at Polus Biopharm, contributing to the global regulatory strategy for insulin biosimilars and global biopharmaceutical business development. She has accumulated experience in global clinical and regulatory affairs at Celltrion, U.K.- and Europe-based consulting firm ProductLife Group (formerly ELC Group) and Otsuka Pharmaceutical.

Following the recent recruitment of Won Sung-yong as the director of the Cell Therapy Research Institute, GC Cell aims to take its R&D strategy and global expansion to the next level with new leadership and expertise, the company said.

"Based on her rich experience and expertise in global pharmaceutical and biotech companies, we expect new CDO Kang further to solidify our cell gene therapy development platform strategy and contribute significantly to introducing our technology and pipeline to the global market," a GC Cell official said.